BD Board Declares 55th Consecutive Dividend Increase and New Share Repurchase Authorization

BD Board of Directors Announces New Dividend Increase and Share Repurchase

In a significant announcement from Franklin Lakes, NJ, BD (Becton, Dickinson and Company), a prominent player in the medical technology sector, has released a proclamation that underscores its continued commitment to shareholder returns. The company's Board of Directors declared a quarterly dividend of $1.06 per common share, marking a 1.0% increase from the previous quarter. This decision signals BD's 55th consecutive year of dividend increases, a noteworthy milestone that keeps the company firmly positioned among the elite group of S&P 500 Dividend Aristocrats—entities that have consistently raised dividends for at least 25 years.

The payment of this dividend is set for December 31, 2026, with the record date being December 10, 2026. This translates to an annual dividend rate of $4.24 per share, reflecting BD's ongoing dedication to rewarding its investors.

In addition to the dividend increase, BD has also authorized the repurchase of up to 10 million shares of its common stock. This move is designed to enhance shareholder value, giving the company flexibility in managing its stock price through various means such as open market purchases or negotiated transactions. The timing and specifics regarding the share repurchases will be guided by several factors, including current market conditions and the overall performance of BD's stock.

BD's chairman, CEO, and president, Tom Polen, commented on this noteworthy announcement, expressing, "This is a reflection of our confidence in our long-term strategy and the value we aim to create for our stakeholders through our New BD strategy. Our commitment to capital returns remains strong while enhancing value for our shareholders."

Founded with a mission to advance healthcare worldwide, BD operates as one of the largest pure-play medical technology companies globally. The company is inherently dedicated to advancing health through innovation across various sectors, including medical essentials, connected care, and biopharma systems. With a workforce exceeding 60,000, BD delivers billions of products annually, thereby positively impacting healthcare on a global scale.

BD's concerted efforts in collaborating closely with healthcare providers ensure that they address pressing clinical needs, bolster operational efficiency, enhance safety, and expand access to necessary medical care. Such innovations are central to optimizing patient care and ensuring better outcomes.

For those interested in sustainability and long-term investments, BD's strategy and focus on returning value to shareholders hold promise. The recent actions taken by the Board not only reflect past successes but also set a strong foundation for future growth in an ever-evolving healthcare landscape.

To learn more about BD and their innovations in medical technology, visit bd.com or engage via their social platforms: LinkedIn, Twitter (@BDandCo), and Instagram (@becton_dickinson). Taking into account the ongoing developments within the organization, stakeholders and potential investors have much to look forward to in the coming quarters as BD continues to drive innovation and shareholder value in the medical technology arena.